The field of diagnosing lung cancer has seen tremendous transformations, thanks to the introduction of technology that has made the diagnosis and treatment of lung cancer simpler. This is because the main challenge in lung cancer diagnosis is that it is detected at its advanced stage.
For a deeper market perspective, explore the lung cancer market analysis.
Liquid Biopsy: Enabling Non-Invasive and Real-Time Diagnostics
Liquid Biopsy has become one of the latest revolutionary inventions used for the diagnosis of lung cancer. Conventional methods include the use of invasive techniques as well as repeat testing; however, liquid biopsy enables the possibility of detecting cancer using blood tests via ctDNA, CTCs, and more.
The latest advances in technology have enabled the use of liquid biopsy from simple biomarker tests to multiple omics, incorporating the use of genomic, epigenomic, and fragmentomic tests. This enables the improved diagnosis of cancer at an earlier stage.
For instance, a recently conducted study in 2023 showed that a liquid biopsy test, aided by artificial intelligence, had the ability to detect early-stage lung cancer with 95% sensitivity.
(Source: exai.bio)
Artificial Intelligence and Radiomics Enhancing Diagnostic Accuracy
There are currently many types of radiology tools developed using artificial intelligence (AI), which are being integrated into imaging and diagnostic workflows, providing much improved accuracy and efficiency for the early detection of lung cancer. These radiology tools utilize AI algorithms to analyze computed tomograms (CTs) and positron emission tomography (PET) images in order to recognize small pulmonary nodules that may be missed through human interpretation alone.
With the improved performance of AI models, in terms of diagnostic accuracy, AI systems are now able to achieve higher levels of accuracy than traditional methods for identifying early-stage tumors, as well as outperforming radiologists.
Radiomics is an area of emerging research that is augmenting AI diagnostic capabilities through quantitative extraction of features from imaging data. When AI is combined with Radiomics techniques, the resulting characterization of tumors becomes more precise and further differentiates between benign and malignant pulmonary nodules.
